ChemLifeIntel/Companies/Neumora

Neumora

HIGH RISKHQ: — · Private · Founded —

LISTINGPrivateFOUNDED0

FOCUS THERAPY AREAS

Manufacturer

COMPANY INTELLIGENCE SNAPSHOTlive

Manufacturing Sites

Intelligence Briefs

Active Regulatory Actions

—

HQ Country

NO ACTIVE REGULATORY ACTIONSClean compliance footprint across 0 monitored sites · HQ

View regulatory detail

INTELLIGENCE

Showing 2 of 2 briefs on Neumora

TRADE & SUPPLY CHAIN·Molecule Spotlight

Neumora Halts Navacaprant Depression Program After Phase 3 Failure: Market Repercussions

Neumora's decision to halt its Navacaprant depression program following Phase 3 failure significantly impacts its pipeline and the Major Depressive Disorder (MDD) landscape. This setback for the kappa opioid receptor (KOR) antagonist class necessitates re-evaluation of R&D strategies and investment in novel CNS therapeutics, posing critical questions for procurement and business development.

90-Day Activity

Neumora

ASArjun Sharma· Senior Intelligence Analyst

2d ago Molecule Spotlight

CLINICAL & PIPELINE·Phase 3 Completion

Neumora's Navacaprant Phase 3 Failure Reshapes Major Depressive Disorder Pipeline and Kappa Opioid Receptor Strategy

Neumora Therapeutics' navacaprant failed Phase 3 trials for major depressive disorder, leading to development cessation. This significantly impacts the kappa opioid receptor antagonist class, prompting a strategic pivot for Neumora and re-evaluation for competitors. Procurement and R&D teams must reassess pipeline risks and market opportunities in MDD, alongside broader shifts in biomanufacturing investment and supply chain resilience.

90-Day Activity

Neumora

LVLakshmi Venkataraman· Senior Intelligence Analyst

2d ago Phase 3 Completion